BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and ...
BridgeBio Oncology Therapeutics Inc. (BBOT) is a clinical-stage biopharmaceutical company dedicated to pioneering advanced small molecule treatments for cancers driven by RAS and PI3Kα, two of the most commonly mutated oncogenes in human cancers. The company was initially formed as an offshoot of BridgeBio Pharma, a biotechnology company founded in ...BridgeBio Oncology Therapeutics Inc. (BBOT) is a clinical-stage biopharmaceutical company dedicated to pioneering advanced small molecule treatments for cancers driven by RAS and PI3Kα, two of the most commonly mutated oncogenes in human cancers. The company was initially formed as an offshoot of BridgeBio Pharma, a biotechnology company founded in 2015 by Neil Kumar, and leverages the expertise of world-leading cancer biologists. BBOT's development pipeline includes several promising programs, notably BBO-8520, BBO-10203, and BBO-11818, which are designed to modulate the KRAS and PI3K pathways. These targets are critical in a variety of solid tumors, including non-small cell lung cancer and colorectal cancer, and represent a significant area of unmet medical need.
In August 2025, BBOT became publicly traded through a business combination with Helix Acquisition Corp. II, a SPAC, successfully raising approximately $450 million in gross proceeds. This capital is intended to fund its clinical development initiatives and advance its pipeline. The company is headquartered in South San Francisco, California, and employs around 92 people, including a leadership team comprising Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer. Dr. Wallace brings extensive experience in oncology drug discovery and development, having previously led research at Amgen and other biotech firms.
Financially, BBOT is a clinical-stage company with no revenues, focusing on research and development. Its market capitalization is approximately $747 million, and it has a strong cash position, with cash per share of $8.10 and a current ratio of 6.16. The company's enterprise value is about $697 million, and it is actively investing in R&D, as evidenced by negative operating cash flow and free cash flow. The company does not pay dividends and has a significant net loss per share of -$4.95, reflecting its stage of development.
Strategically, BBOT aims to become a leader in precision oncology, targeting genetic drivers of cancer with best-in-class small molecules. The company's mission is to transform the lives of patients with RAS and PI3Kα-driven cancers, and it is positioned to capitalize on the growing demand for targeted therapies in oncology.
